EGFR and non-small cell lung carcinoma: The outstanding efficacy and good safety profile of our case indicate that the combination therapy of afatinib and anlotinib can be considered as a viable treatment option for patients with rare EGFR mutations, specifically L858M/L861R compound mutations in NSCLC.